반려동물용 귀 감염 치료 시장 : 약물 유형별, 동물 유형별, 투약 유형별, 질환 유형별, 유통 채널별, 세계 예측(2024-2032년)

Companion animal ear infection treatment market size is likely to register 6.8% CAGR between 2024 to 2032, driven by the increasing prevalence of ear infections among companion animals, such as dogs and cats. As per American Kennel Club, around 20% dogs have some form of ear disease, which could affect one or both ears. The rising count of ear infections including environmental allergens, ear mites, bacterial or yeast overgrowth, and anatomical predispositions will subsequently boost the market growth.

Moreover, technological advancements in veterinary medicine have led to the development of innovative treatment options for companion animal ear infections. These advancements include the introduction of novel drug delivery systems, such as long-acting ear drops and topical formulations, which enhance treatment efficacy and patient compliance. The expansion of the pet healthcare sector, coupled with the increasing adoption of companion animals, particularly in urban areas, will further contribute to the industry expansion.

The companion animal ear infection treatment industry is segmented based on drug type, animal type, medication type, mode of administration, disease type, distribution channel and region.

By mode of administration, the market size from the oral segment is anticipated to witness 6.8% CAGR through 2032, attributed to the convenience and efficacy of oral medications. Oral antibiotics and antifungal medications offer a systemic approach to combating infections, reaching areas of the ear canal that may be difficult to access with topical treatments alone. Additionally, advancements in veterinary pharmaceuticals have led to the development of oral medications with improved safety profiles and palatability for increasing patient compliance and treatment success rates.

The drug store distribution channel segment in the companion animal ear infection treatment industry is estimated to strike 6.9% CAGR during 2024-2032. Increasing pet ownership rates and awareness about pet healthcare will drive the demand for convenient and accessible treatment options for common ailments like ear infections. The convenience of purchasing ear infection treatments alongside other pet care products at drug stores is further appealing to pet owners seeking quick and cost-effective solutions to manage the health of their pets.

Europe companion animal ear infection treatment industry size will record 6.8% CAGR between 2024-2032, attributed to stringent regulations governing pet healthcare standards and the increasing emphasis on preventive veterinary care. The high pet ownership rates in countries like Germany, France, and the U.K., coupled with the growing disposable income of pet owners will foster a conducive market environment. Furthermore, advancements in veterinary medicine, including the availability of specialized ear infection treatment products and diagnostic tools to enhance the efficacy of treatment will drive regional the market growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing rate of pet ownership globally
    • 3.2.1.2 Growing advancements in veterinary medicine
    • 3.2.1.3 Rising prevalence of ear infections among pets
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Lack of compliance
    • 3.2.2.2 Side effects of medications
• 3.3 Growth potential analysis
• 3.4 Pipeline assessment
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
  • 3.6.1 Supplier power
  • 3.6.2 Buyer power
  • 3.6.3 Threat of new entrants
  • 3.6.4 Threat of substitutes
  • 3.6.5 Industry rivalry
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Antibiotics
  • 5.2.1 Cephalosporins
  • 5.2.2 Penicillins
  • 5.2.3 Fluoroquinolones
  • 5.2.4 Imidazole
  • 5.2.5 Other antibiotics
• 5.3 Antifungals
• 5.4 Corticosteroids
• 5.5 Cleaning agents
• 5.6 Other drug types

Chapter 6 Market Estimates and Forecast, By Animal Type, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Dogs
• 6.3 Cats
• 6.4 Horses
• 6.5 Other animal types

Chapter 7 Market Estimates and Forecast, By Medication Type, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 OTC
• 7.3 Prescription

Chapter 8 Market Estimates and Forecast, By Mode of Administration, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Otic
• 8.3 Oral
• 8.4 Parenteral
• 8.5 Topical

Chapter 9 Market Estimates and Forecast, By Disease Type, 2018 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Otitis externa
• 9.3 Otitis media
• 9.4 Otitis interna

Chapter 10 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 Veterinary hospital pharmacies
• 10.3 Drug stores
• 10.4 Pet specialty stores
• 10.5 E-commerce

Chapter 11 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 11.1 Key trends, by region
• 11.2 North America
  • 11.2.1 U.S.
  • 11.2.2 Canada
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 France
  • 11.3.4 Spain
  • 11.3.5 Italy
  • 11.3.6 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 Japan
  • 11.4.2 China
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 Rest of Asia Pacific
• 11.5 Latin America
  • 11.5.1 Brazil
  • 11.5.2 Mexico
  • 11.5.3 Rest of Latin America
• 11.6 Middle East and Africa
  • 11.6.1 South Africa
  • 11.6.2 Saudi Arabia
  • 11.6.3 Rest of Middle East and Africa

Chapter 12 Company Profiles

• 12.1 Bayer AG
• 12.2 Ceva Sante Animale
• 12.3 Dechra Pharmaceuticals PLC
• 12.4 Elanco Animal Health Incorporated
• 12.5 Entod International
• 12.6 Merck & Co., Inc.
• 12.7 Nextmune
• 12.8 Penn Veterinary Supply, Inc.
• 12.9 Piedmont Animal Health, Inc.
• 12.10 Vedco, Inc.
• 12.11 Vetnique Labs
• 12.12 Vetoquinol S.A.
• 12.13 Virbac S.A.
• 12.14 Wedgewood Village Pharmacy, LLC
• 12.15 Zoetis Inc.